MYO antibody

Myoglobin (MYO) is applied for early screening of acute myocardial infarction and evaluation of striated muscle damage in patients with suspected muscle injury. MYO OEM kit utilizes a two-antibody sandwich immunoassay and is applicable to chemiluminescence platforms. Specific antibodies target MYO epitopes to capture trace plasma MYO, delivering high sensitivity and specificity. Calibrated with high-purity recombinant MYO, the assay provides accurate and stable quantitative results. Serving as a vital early biomarker for acute myocardial infarction diagnosis, it supports early identification and dynamic monitoring of myocardial and skeletal muscle injury for clinical auxiliary diagnosis. Myoglobin (MYO) is a protein uniquely present in human striated muscle and exists at low levels in healthy serum. It leaks into circulation when cardiac or skeletal muscle is injured. Thanks to its small molecular size, MYO elevates early: in AMI patients, levels increase 2–3 hours after symptom onset, peak within 7–10 hours and normalize around 24 hours, making MYO a key marker for AMI testing. Serum MYO assay aids diagnosis of myocardial infarction, muscular dystrophy, myocarditis and cardiomyopathy, as well as assessment of treatment response and prognosis. ★Bulk reagents are available with matching raw materials.